Best Infectious Diseases Companies in Germany
The 78 best Infectious Diseases companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CureVac.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Germany
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CureVac Developer of mRNA-based therapeutics against cancer and infectious diseases 55Patents top 20%Funding top 28%Moat top 29%Innovation top 32% All 11 signals ▾Patentstop 20% Fundingtop 28% Moattop 29% Innovationtop 32% Partnerstop 41% Markettop 43% Newstop 45% Talenttop 49% Techbottom 49% Globalbottom 46% Growthbottom 38% Patents: 1,737 patents matched (strict assignee match) · 461 filings since 2022 vs 745 in 2017-21 Funding: Raised $975M across 14 rounds · 14 rounds over 23 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $975M | 69 mo ago | 648 648 → 678 (+5%) | 2000 | Florian Mulbe Co-Founder & CPO | WordPressApple iCloud MailMicrosoft 365+20 | 13 signals ▼50% M&A · Regulatory · Earnings | 1,728 patents Patents concentrated in health & consumer products | — |
| 2 | Curetis Provider of molecular diagnostics platform to detect infectious diseases | $127M | 68 mo ago | 55 | 2007 | Raju Jha CEO | Wix eCommerceWixSentry+10 | — | 79 patents Automated nucleic acid extraction and sample lysis technologies for molecular diagnostic platforms. | — |
| 3 | AiCuris Developer of antiviral and antibacterial therapeutics for infectious diseases | $75M | 103 mo ago | 61 61 → 80 (+31%) | 2006 | — | WordPressApple iCloud MailMicrosoft 365+19 | 3 signals M&A | 1,119 patents Antiviral therapeutics targeting herpesvirus nuclear egress and intravaginal drug delivery | — |
| 4 | Apogenix Developer of novel protein therapeutics for the treatment of cancer and inflammatory diseases | $72M | 54 mo ago | 57 | 2005 | — | — | — | 369 patents Engineered multi-specific protein agonists for immune checkpoint modulation and cancer therapy | — |
| 5 | Morphochem German, late clinical stage biopharma developing oxazolidinone antibiotics for clostridium difficile… | $68M | 299 mo ago | 1 | 1998 | Alexis Rideau CEO | — | — | 28 patents Hybrid oxazolidinone‑quinolone antibiotics for parenteral bacterial infection treatment | — |
| 6 | Adrenomed Drug to treat severe sepsis | $54M | 66 mo ago | 18 18 → 17 (-6%) | 2009 | Bernd Wegener Co-Founder | — | — | 219 patents Therapeutic antibodies and binders targeting adrenomedullin for shock and disease treatment | 1 launch |
| 7 | Allecra Developer of antibiotics for the treatment of multi-drug-resistant bacterial infections | $44M | 120 mo ago | 10 | 2013 | Andreas Kranzusch Managing Director | — | — | — | — |
| 8 | SphingoTec Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases 55Growth top 20%Moat top 21%Funding top 32%Patents top 35% All 10 signals ▾Growthtop 20% Moattop 21% Fundingtop 32% Patentstop 35% Talenttop 38% Innovationtop 41% Globalbottom 40% Marketbottom 38% Techbottom 32% Newsbottom 18% Growth: Headcount 23 → 36 (+57%) across vintages · Fresh capital in last 24 mo Moat: Editorial + unicorn rating 7/10 · IP moat: 264 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $36M | 22 mo ago | 36 36 → 19 (-47%) | 2002 | Andreas Bergmann Founder | Cart FunctionalityTYPO3 CMSPHP+13 | — | 263 patents Peptide biomarker diagnostic assays for kidney, sepsis, and dementia monitoring | 4 launchs |
| 9 | CPTx Developer of programmable DNA therapeutics for a range of medical challenges 40Growth top 35%Funding top 37%Moat top 38%Talent top 38% All 9 signals ▾Growthtop 35% Fundingtop 37% Moattop 38% Talenttop 38% Techtop 46% Patentstop 50% Innovationbottom 43% Globalbottom 31% Marketbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $29.0M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $29M | 20 mo ago | — | 2021 | Christian Sigl Founder & CTO | WordPressMySQLPHP+19 | — | 4 patents Formulation and delivery of nucleic‑acid‑based pharmaceuticals | — |
| 10 | SpinDiag Developer of point-of-care system for screening drug-resistant pathogens | $28M | 44 mo ago | 74 | 2016 | Frank Schwemmer Co-Founder | — | — | 39 patents Magnetic‑rotational sample preparation and lysis for nucleic‑acid extraction and analysis | — |
| 11 | Innovative Molecules Developer of drugs to treat Herpes simplex-induced diseases | $24M | 60 mo ago | — | 2003 | Gerald Kleymann Founder & CEO | MODXPHPUNIX+7 | — | 102 patents Antiviral small‑molecule thiazole/helicase‑primase inhibitors, including deuterated, enantiomeric, solid forms. | — |
| 12 | GNA Biosolutions Develops instruments, OEM modules and assays for molecular pathogen detection | $20M | 82 mo ago | 29 | 2010 | — | — | — | 96 patents Patents concentrated in chemistry & materials | — |
| 13 | Atriva Therapeutics Re-purposing MEK inhibitors to treat viral infections including COVID-19 and influenza | $14M | 68 mo ago | 13 | 2015 | Rainer Lichtenberger Advisor to the CEO | — | — | 112 patents MEK kinase inhibitor therapeutics for viral, bacterial, and hantavirus infections | — |
| 14 | Kupando Developer of immunotherapeutics for cancer 11News top 32%Funding top 40%Moat top 48%Talent bottom 41% All 6 signals ▾Newstop 32% Fundingtop 40% Moattop 48% Talentbottom 41% Globalbottom 37% Marketbottom 23% News: 4 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding, Leadership Funding: Raised $12.6M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 11/100 | $13M | 3 mo ago | 5 | 2018 | Johanna Holldack Founder & CEO | — | 4 signals Funding · Leadership | — | — |
| 15 | MYR Surface peptide fragment for treating Hepatitis B and D infections | $10M | 171 mo ago | 22 | 2010 | Jorn Moller Co-Founder | — | — | 24 patents Combination antiviral therapies for HBV/HDV and NLRP3 inflammasome inhibitor drugs | — |
| 16 | ImevaX Vaccines for chronic and nosocomical infections | $10M | 135 mo ago | 1 | 2014 | — | — | — | 20 patents Therapeutic treatments targeting Helicobacter pylori infections | — |
| 17 | PROSION Developer of precision medicine technology for cancer treatment | $6M | 50 mo ago | 10 | 2020 | Mutlu Yonel Co-Founder | WebflowApple iCloud MailMicrosoft 365+9 | — | — | — |
| 18 | ARTCLINE Developer of immune cell-based extracorporeal therapies for intensive care medicine | $5M | 26 mo ago | — | 2007 | Jens Altrichter Co-Founder & CEO | — | — | 19 patents Leukocyte-based cell therapy manufacturing and immune cell treatment formulations. | — |
| 19 | Rodos BioTarget Provider of drug delivery platform for the treatment of bacterial infections and viral diseases | $5M | 106 mo ago | 4 | 2008 | — | — | — | 29 patents Lipid‑based targeted nanocarriers for gene and drug delivery to immune and neural cells | — |
| 20 | AMP Therapeutics Developer of treatments for multi-drug-resistant gram-negative infections | $5M | 163 mo ago | 3 | 2009 | — | — | — | — | — |
| 21 | FRIZ Biochem DNA-chip based biosensor for SNP detection | $3M | 138 mo ago | — | 2003 | Gerhard Hartwich CEO | — | — | 63 patents Patents concentrated in transport & manufacturing processes | — |
| 22 | Abviris Provider of diagnostics solutions for HPV infections | $2M | 63 mo ago | 5 | 2014 | Stefan Raupach Co-Founder & General Manager | — | — | — | — |
| 23 | smartbax Developer of multi-targeted antibacterial compounds 14Talent top 38%News top 43%Moat top 48%Funding top 49% All 6 signals ▾Talenttop 38% Newstop 43% Moattop 48% Fundingtop 49% Globalbottom 32% Marketbottom 22% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated News: 2 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding rank vs industry peers · Fliar Intelligence Index 14/100 | $2M | 8 mo ago | 3 | 2021 | Stephan Sieber Co-Founder | — | — | — | — |
| 24 | Nebula Biocdes Provider of disinfectant solutions for infection control | $2M | 55 mo ago | — | 2019 | Ansgar Schmidt-Bleker Co-Founder & Co-CEO | — | — | — | — |
| 25 | Molzym Manufacturer of reagents and products for pathogen detection and DNA isolation | $1M | 133 mo ago | 25 | 2003 | — | JoomlaPHPUIKit+9 | — | 15 patents Microbial DNA extraction and purification technologies for nucleic acid analysis | — |
| 26 | ImmunoLogik Developer of novel antiviral drug candidates targeting host cell structures | $630K | 58 mo ago | 2 | 2012 | Ulrich Schubert Co-Founder | — | — | 26 patents Antiviral therapeutics targeting coronavirus/retrovirus via small-molecule and lectin inhibitors | — |
| 27 | Invitris Developer of drugs for treating antibiotic-resistant infections | $125K | 37 mo ago | 10 | 2019 | Kilian Vogele Co-Founder & CTO | Node.jsThree.jsRadix UI+11 | — | 5 patents Continuous protein production and engineered multispecific particle platforms | 1 internship |
Top 12 Infectious Diseases companies in Germany
#1
Series A · Schonefeld, Brandenburg · founded 2018 · 5 employees$12.6Mraised▾
Developer of immunotherapeutics for cancer. It offers a lead candidate KUP101 an immunostimulatory agent co-encapsulated in a liposomal formulation for the treatment of solid tumors in combination with other drugs.
- Mar 2026Series A$11.5M
- Sep 2022Series A$12.6M
#2
Seed · Munich, Bavaria · founded 2021 · 3 employees$2.1Mraised▾
Developer of multi-targeted antibacterial compounds. The company creates multi-targeted antibacterial compounds that are effective against multi-drug resistance infections such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
- Oct 2025Seed$5.5M
- May 2023Seed$1.3M
- Seed—
#3
Series C · Hennigsdorf, Brandenburg · founded 2002 · 36 employees$36.1Mraised▾
Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases. The company is involved in the development of biomarker-based in-vitro diagnostic solutions for the treatment of critical medical conditions, such as sepsis, acute heart failure, circulatory failure, and acute kidney injury. It develops a PenKid platform that measures the levels of renal hormone enkephalin and uses it to predict creatinine levels in the near future. Bio-ADM measures levels of Adrenomedullin as a biomarker for circulatory shock and vasopressor demand. It has also developed a pro-NT biomarker that measures the levels of proneurotensin to predict the risk of obesity, cardiovascular disease, and breast cancer. It provides a vr-hGH platform that measures levels of human growth hormone to predict cardiovascular risk in men.
- Aug 2024Series C$5.5M
- Dec 2019Series B$7.6M
- Oct 2018Series A$23M
- 2018Seed—
#4
Series B · Planegg, Bavaria · founded 2021$29Mraised▾
Developer of programmable DNA therapeutics for a range of medical challenges. The company leverages its proprietary technology to deliver precision medicine solutions, utilizing a programmable DNA-based approach to target specific diseases such as viruses, cancer, and autoimmune diseases.
- Sep 2024Series B$29M
#5
Acquired · Tubingen, Baden Wurttemberg · founded 2000 · 648 employees$975.3Mraised▾
Developer of mRNA-based therapeutics against cancer and infectious diseases. It has developed RNAntibody to enable the expression of functional antibodies and antibody-like proteins from mRNA. The lead product includes CV9104, an investigational therapeutic vaccine to treat prostate cancer. The vaccine is injected into the skin to stimulate the body's immune system to destroy prostate cancer cells. The company's other product includes CV8102 for cutaneous myeloma and CV9202 used to treat patients with non-small cell lung cancer.
- Sep 2020Grant (prize money)$299M
- Jul 2020Series F$126M
- Jul 2020Series F$171M
- Jul 2020Conventional Debt$84.3M
#6
Acquired · Holzgerlingen, Baden Wurttemberg · founded 2007 · 55 employees$127.1Mraised▾
Curetis provides a molecular diagnostics device to detect infectious diseases. The company focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases. The company develops the Unyvero A50 System for the detection of bacterial infections using PCR technology in hospitalized patients. Using a variety of cartridges, diseases such as pneumonia or implant and tissue infections can also be diagnosed within 4–5 hours.
- Sep 2020Grant (prize money)$409.7K
- Jul 2020Conventional Debt$5.7M
- May 2019Series C$1.7M
- May 2019Conventional Debt$5.6M
#7
Series B · Heidelberg, Baden-wurttemberg · founded 2005 · 57 employees$72.3Mraised▾
Developer of novel protein therapeutics for the treatment of cancer and inflammatory diseases. The compound´s mechanism of action is either based on the targeted modulation of the programmed cell death or on the inhibition of tumour cell growth. The lead product is APG101 (fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an IgG antibody) is being developed for the treatment of Glioblastoma multiforme and myelodysplastic syndrome.
- Dec 2021Series B$29.4M
- Apr 2008Series B$42.9M
#8
Series B · Freiburg im Breisgau, Baden Wurttemberg · founded 2016 · 74 employees$27.7Mraised▾
SpinDiag, a spin-off of Hahn-Schickard, develops a point-of-care system. The automated system helps in the screening drug-resistant pathogens. The system, LabDisk, is based on a patented centrifugal-microfluidic technology which provides PCR results directly from patient swab samples.
- Oct 2022Conventional Debt$14.6M
- May 2020Series B$17.8M
- Apr 2020Series B$6.5M
- Nov 2018Series A$3.4M
#9
Series A · Germany · founded 2007$4.8Mraised▾
Developer of immune cell-based extracorporeal therapies for intensive care medicine. The company focuses on clinical trials and further development of therapies. Their therapy aims for effectiveness, safety, and ease of use. The company develops therapies for patients and medical practitioners. It identifies immunological causes and interactions. The company transfers medical inventions from university research to industrial applications.
- Mar 2024Series A$4.8M
#10
Series E · Hohen Neuendorf, Brandenburg · founded 2009 · 18 employees$53.8Mraised▾
Adrenomed focuses on developing drugs to treat severe sepsis. Sepsis involves an overactive inflammatory response to severe bacterial infection that can compromise the vascular integrity and cause tissue edema, organ dysfunction and death. Its drug adrenomedullin is a peptide with 52 amino acids and has strong vasodilator activity.
- Nov 2020Series E$26.6M
- Nov 2018Series D$27.2M
#11
Acquired · Wuppertal, North Rhine Westphalia · founded 2006 · 61 employees$74.8Mraised▾
Developer of antiviral and antibacterial therapeutics for infectious diseases. The pipeline includes the development of AIC246 (Prevymis) for treating human cytomegalovirus (quinazoline-based inhibitor of the cytomegalovirus (CMV) terminase protein), AIC316 (phase II) for the treatment Herpes simplex, and AIC649 (Phase I) for Hepatitis B virus.
- Nov 2017Grant (prize money)—
- Jan 2017Grant (prize money)$262.3K
- Mar 2015Grant (prize money)$278.1K
- Apr 2010Series B$74.8M
#12
Acquired · Munich, Bavaria · founded 1998 · 1 employees$68Mraised▾
Morphochem is a German, late clinical stage biopharma developing Oxazolidinone antibiotics for Clostridium infections. The company is a full subsidiary of Biovertis (funded by TVM Capital). Its lead candidate MCB3681 is targeted at the intravenous therapy of severe CDI and is in phase 2 trials (as on Aug.2017). It claims that in its preclinical studies, the candidate has demonstrated gram-positive antimicrobial activity and was particularly effective against C. diff clinical isolates regardless of their virulence.
- Jul 2001Series C$12.8M
- Aug 2000Series B$37.5M
- Sep 1999Series A$15.5M
- 1998Unattributed$2.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in Germany
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,717 Germany-affiliated papers.
- Heidelberg University249
- German Cancer Research Center150
- Charité - Universitätsmedizin Berlin135
- University Medical Center Hamburg-Eppendorf127
- Universität Hamburg107
- Liquid biopsy14→68
- Cancer7→24
- Biomarker2→18
- Biopsy2→16
- DNA sequencing2→14
- Liquid biopsy42→156
- Point-of-care testing40→93
- Biopsy5→52
- Biomarker9→52
- Oncology9→47
- Liquid biopsy19→65
- Biopsy5→31
- Point-of-care testing26→49
- Internal medicine4→19
- Cell-free fetal DNA2→13
Where diagnostics is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing diagnostics patents in Germany
Germany diagnostics patent filing is steady — 17 filings from 15 assignees (2016–2025), led by Siemens, Roche Diagnostics, Hoffmann LA Roche; annual filings 3→3.
- Siemens7
- Roche Diagnostics5
- Hoffmann LA Roche5
- Fraunhofer GES Forschung3
- Ronda Cornelis R1
- Popov IGOR1
- UNIV Koeln1
- Earlybio1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.